Assetmark Inc. Raises Holdings in Edwards Lifesciences Corporation $EW

Assetmark Inc. boosted its holdings in shares of Edwards Lifesciences Corporation (NYSE:EW) by 344.7% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 2,735 shares of the medical research company’s stock after acquiring an additional 2,120 shares during the period. Assetmark Inc.’s holdings in Edwards Lifesciences were worth $214,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently bought and sold shares of the company. Rosenberg Matthew Hamilton acquired a new position in shares of Edwards Lifesciences in the 2nd quarter valued at $28,000. Quantbot Technologies LP purchased a new position in shares of Edwards Lifesciences in the 1st quarter valued at about $26,000. SouthState Corp acquired a new stake in Edwards Lifesciences during the first quarter worth approximately $27,000. Costello Asset Management INC acquired a new position in Edwards Lifesciences in the first quarter valued at $29,000. Finally, Riverview Trust Co increased its holdings in shares of Edwards Lifesciences by 44.5% in the 2nd quarter. Riverview Trust Co now owns 516 shares of the medical research company’s stock valued at $40,000 after acquiring an additional 159 shares during the period. 79.46% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity at Edwards Lifesciences

In other news, insider Larry L. Wood sold 8,950 shares of the firm’s stock in a transaction on Monday, August 18th. The stock was sold at an average price of $78.06, for a total transaction of $698,637.00. Following the completion of the sale, the insider directly owned 206,900 shares of the company’s stock, valued at $16,150,614. This trade represents a 4.15% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 1.29% of the company’s stock.

Edwards Lifesciences Stock Performance

EW opened at $83.37 on Friday. The stock has a market cap of $48.95 billion, a PE ratio of 12.00, a price-to-earnings-growth ratio of 3.97 and a beta of 1.03. The business’s 50 day moving average is $77.78 and its 200-day moving average is $77.36. Edwards Lifesciences Corporation has a twelve month low of $64.89 and a twelve month high of $87.09. The company has a current ratio of 4.68, a quick ratio of 3.87 and a debt-to-equity ratio of 0.06.

Edwards Lifesciences (NYSE:EW) last released its earnings results on Thursday, October 30th. The medical research company reported $0.67 EPS for the quarter, beating the consensus estimate of $0.59 by $0.08. The firm had revenue of $1.55 billion for the quarter, compared to analysts’ expectations of $1.49 billion. Edwards Lifesciences had a net margin of 72.96% and a return on equity of 15.01%. Edwards Lifesciences’s quarterly revenue was up 14.7% on a year-over-year basis. During the same quarter last year, the company earned $0.67 EPS. Edwards Lifesciences has set its FY 2025 guidance at 2.560-2.620 EPS. Q4 2025 guidance at 0.580-0.640 EPS. On average, analysts predict that Edwards Lifesciences Corporation will post 2.45 earnings per share for the current year.

Analyst Ratings Changes

A number of brokerages have commented on EW. Oppenheimer downgraded shares of Edwards Lifesciences from an “outperform” rating to a “market perform” rating in a research report on Wednesday, October 8th. Piper Sandler reissued an “overweight” rating and issued a $95.00 price objective (up previously from $90.00) on shares of Edwards Lifesciences in a research report on Friday, October 31st. National Bankshares set a $92.00 price target on shares of Edwards Lifesciences in a research note on Friday, October 31st. Royal Bank Of Canada increased their target price on shares of Edwards Lifesciences from $89.00 to $95.00 and gave the stock an “outperform” rating in a research report on Friday, October 31st. Finally, Mizuho upped their price target on Edwards Lifesciences from $90.00 to $100.00 and gave the stock an “outperform” rating in a report on Friday, October 31st. Three research analysts have rated the stock with a Strong Buy rating, fourteen have given a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average price target of $91.39.

Edwards Lifesciences Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.